false 0001335105 0001335105 2024-08-19 2024-08-19 0001335105 us-gaap:CommonStockMember 2024-08-19 2024-08-19 0001335105 LIXT:WarrantToPurchaseCommonStockMember 2024-08-19 2024-08-19 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): August 19, 2024

 

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

 

delaware   001-39717   20-2903526

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

680 East Colorado Boulevard, Suite 180

Pasadena, California 91101

(Address of principal executive offices)

 

(631) 830-7092

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (See General Instruction A.2. below):

 

☐Written communications pursuant to Rule 425 under the Securities Act of 1933 (17 CFR 230.425)
  
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
☐Pre-commencement communications pursuant to Rule 13e-4(e) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock   LIXT   The Nasdaq Stock Market LLC
Warrant to Purchase Common Stock   LIXTW   The Nasdaq Stock Market LLC

 

 

 

 

 

 

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

 

On August 19, 2024, Lixte Biotechnology Holdings, Inc. (the “Company”) received a deficiency letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires the Company to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing on The Nasdaq Capital Market (the “Stockholders’ Equity Requirement”).

 

Pursuant to the Notice, the Company has 45 calendar days from the date of the Notice to submit a plan to regain compliance, and the Company intends to submit such a plan during this period. If it accepts the plan, Nasdaq can grant an extension of up to 180 calendar days from the date of the Notice to evidence compliance. In the event the plan is not accepted by Nasdaq, or in the event the plan is accepted by Nasdaq and the 180-day extension period is granted, but the Company fails to regain compliance within such plan period, the Company would have the right to a hearing before an independent panel. The hearing request would stay any suspension or delisting action pending the conclusion of the hearing process and the expiration of any additional extension period granted by the panel following the hearing.

 

The Company intends to take all reasonable measures available to regain compliance under the Nasdaq Listing Rules and to remain listed on Nasdaq. However, there can be no assurances that Nasdaq would grant the Company’s request for an extension or that the Company would ultimately be able to regain compliance with all applicable requirements for continued listing on the Nasdaq Capital Market.

 

Neither the Notice nor the Company’s noncompliance have an immediate effect on the listing or trading of the Company’s common shares and warrants, which will continue to trade on The Nasdaq Capital Market under the symbols “LIXT” and “LIXTW”, respectively.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: August 23, 2024 LIXTE BIOTECHNOLOGY HOLDINGS, INC.
  (Registrant)
     
  By:/s/ BASTIAAN VAN DER BAAN
    Bastiaan van der Baan
    Chief Executive Officer

 

 

 

v3.24.2.u1
Cover
Aug. 19, 2024
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 19, 2024
Entity File Number 001-39717
Entity Registrant Name LIXTE BIOTECHNOLOGY HOLDINGS, INC.
Entity Central Index Key 0001335105
Entity Tax Identification Number 20-2903526
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 680 East Colorado Boulevard
Entity Address, Address Line Two Suite 180
Entity Address, City or Town Pasadena
Entity Address, State or Province CA
Entity Address, Postal Zip Code 91101
City Area Code (631)
Local Phone Number 830-7092
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Common Stock [Member]  
Title of 12(b) Security Common Stock
Trading Symbol LIXT
Security Exchange Name NASDAQ
Warrant to Purchase Common Stock  
Title of 12(b) Security Warrant to Purchase Common Stock
Trading Symbol LIXTW
Security Exchange Name NASDAQ
Lixte Biotechnology (NASDAQ:LIXT)
Gráfico Histórico do Ativo
De Out 2024 até Nov 2024 Click aqui para mais gráficos Lixte Biotechnology.
Lixte Biotechnology (NASDAQ:LIXT)
Gráfico Histórico do Ativo
De Nov 2023 até Nov 2024 Click aqui para mais gráficos Lixte Biotechnology.